Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Summary

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Timeline

Start

2024-02-29

Primary completion

2025-06-19

Completion

2025-12-01

Outcome

Missed primary endpoint

release “The overall KARDIA-3 study did not meet the pre-specified definition for statistical significance” gene.com ↗

Drugs

Indications